NR for long COVID: higher NAD did not establish symptom benefit

The controlled result comes first

A randomized trial of nicotinamide riboside in long COVID raised NAD but did not demonstrate a significant advantage over placebo in its cognitive or symptom outcomes. ^[1] That is the main finding to keep in view. The paper also reported exploratory within-group improvements, which can be interesting without changing the controlled conclusion. This distinction matters because a supplement summary can quote a real improvement from baseline while leaving readers with the impression that the treatment outperformed placebo. The useful interpretation asks which comparison was made, what was prespecified and whether the result answers the patient’s actual question about feeling or functioning better.

The trial included a delayed-start group

The single-center study randomized fifty-eight community-dwelling participants with long COVID in a two-to-one allocation. One group received NR for twenty weeks; the other received placebo for ten weeks and then NR for ten weeks. The oral research regimen was 2,000 mg daily within a twenty-four-week trial framework that included a lead-in. ^{[1] [2]} That is a study description, not a personal amount to copy. The design allowed an initial placebo comparison and later exploratory observations after both groups had received NR. Those stages should not be combined into a single unqualified statement that the supplement improved long COVID.

NAD changed more clearly than cognition

The NR group’s NAD levels rose about 2.6- to 3.1-fold after five to ten weeks and remained elevated during later treatment. However, between-group comparisons for the cognitive measures were not significant, with reported P values from 0.47 to 0.74. Fatigue, sleep, anxiety and depression also showed no significant treatment advantage over placebo. ^[1] This is an example of target engagement without established clinical benefit. It does not mean the biological measurement was meaningless. It means that the measurable change did not, in this experiment, establish the symptom improvement that would justify the treatment claim most readers are considering.

For the measurement distinction, read what a higher NAD result establishes.

The exploratory improvement is a different analysis

The investigators later pooled participants’ first periods on NR and examined changes from their own baselines without multiplicity adjustment. Some outcomes improved in that exploratory analysis. ^[1] Such an observation can help plan another trial, but it is less persuasive than a randomized between-group comparison for determining whether NR caused the improvement. Symptoms can fluctuate, repeated testing can change performance and people may improve over time for reasons unrelated to the supplement. These are reasons to preserve the comparison, not to dismiss patients’ experiences. A careful summary should allow both statements to be true: exploratory changes occurred, while controlled benefit remained unproven. A meaningful next study would prespecify which symptom change counts as useful to patients and how missing outcomes will be handled. That makes the result harder to reinterpret around whichever measure happens to improve after treatment begins.

Attrition makes the result harder to interpret

Dropout was substantial and uneven. The NR-first group had reported dropout of 32.4 percent by ten weeks and 51.4 percent by twenty weeks, compared with 14.3 percent at each point in the delayed-start group. ^[1] Attrition can leave a smaller, selected group providing the later measurements. It also makes estimates less precise and complicates interpretation of within-group changes. The appropriate response is neither to declare the trial useless nor to treat the remaining participants as a complete answer. A larger study would need to understand why people leave, preserve follow-up and determine whether the intervention provides a practical benefit under realistic conditions.

Safety is not established by one small experiment

The report described one serious adverse event considered unrelated to the study intervention. ^[1] That is a bounded observation, not proof that the regimen is suitable for everyone with long COVID or for indefinite use. The research population and exclusions limit generalization, and the tested amount should not become a self-prescribed response to a laboratory result. Bring any supplement proposal to the clinician managing the condition, including the complete product label and other medicines. A retail blend may also contain ingredients beyond NR, so its tolerability cannot simply be inherited from an experiment using a different preparation.

Long COVID care remains individualized

CDC guidance emphasizes care directed toward a person’s symptoms and function, with attention to factors such as post-exertional malaise. ^[3] That context is important when evaluating a general energy or mitochondrial-support claim. A product that sounds relevant to fatigue does not automatically fit a patient whose symptoms worsen after exertion or whose care requires several coordinated approaches. The NR study does not establish a reason to abandon symptom management, pacing advice or investigation of other treatable problems. It adds a specific research result to the discussion, and that result is more informative when its null controlled findings remain visible.

The implication for an NR purchase

The trial is not a strong basis for buying NR as an established long-COVID treatment. It supports the narrower conclusion that NAD can rise during supplementation while meaningful symptom superiority remains uncertain. A reader who still wants to discuss the option should separate the clinical decision from the brand comparison. The study did not establish that one commercial capsule, liquid or combination is best, and a higher milligram number does not solve the missing efficacy question. Compare the actual label and recurring cost only after the purpose is clear. The most defensible next step is a clinically informed discussion, not a product recommendation built mainly from an exploratory before-and-after result.

To see how a retail blend differs from NR alone, read our Momentous Longevity review; the review does not establish long-COVID efficacy.